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The widely recognized neuroprotective effect of iron chelators is contributed by their
ability to prevent reactive oxygen species (ROS) generation via the Fenton reaction,
which sequesters redox-active Fe. An additional neuroprotective mechanism of iron-
chelating compounds is to regulate the transcriptional activator hypoxia-inducible
factor 1α (HIF-1α). In the present study, we observed that intranasal administration of
deferoxamine decreased beta-amyloid (Aβ) deposition and rescued synapse loss in
the brain of Aβ precursor protein and presenilin-1 (APP/PS1) double transgenic mice.
We found that deferoxamine (DFO) up-regulated HIF-1α mRNA expression and its
protein level, and further induced the proteins that are encoded from HIF-1-adaptive
genes, including transferrin receptor (TFR), divalent metal transporter 1 (DMT1), and
brain-derived neurotrophic factor (BDNF). The effects of DFO on the induction and
stabilization of HIF-1α were further confirmed in vitro. This was accompanied by a
decrease of Fe in the CA3 region of the hippocampus. Western blotting studies revealed
that DFO differentially enhanced the phosphorylation of mitogen-activated protein kinase
(MAPK)/P38 kinase in vitro and in vivo. The results suggest that the DFO may up-
regulate several HIF-1-dependent neuroprotective-adaptive genes in AD via activating
P38/HIF-1α pathway, which may serve as important therapeutic targets to the disease.
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Introduction
Alzheimer’s disease (AD) is the most common and progressive neurodegenerative disease.
There is no effective therapy for AD. One of the characteristics of the disease is the
presence of beta amyloid protein aggregates and cell and synapse loss. A large body of
evidence suggests that the etiology of AD is multifactorial and results from interactions
among genetic, environmental, and endogenous factors (Migliore and Coppedè, 2009).
Abbreviations: Aβ, amyloid-β; AD, Alzheimer’s disease; APP, amyloid precursor protein; APPsw, amyloid precursor
protein Swedish mutant; BACE1, β-Site APP cleaving enzyme 1; BDNF, brain-derived neurotrophic factor; DFO,
deferoxamine; DMT1, divalent metal transporter 1; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GSK-
3β, glycogen synthase kinase-3β; HIF, hypoxia inducible factor; HRE, hypoxia-response element; HRP, horseradish
peroxidase; IHC, immunohistochemistry; MAPK, mitogen-activated protein kinase; PS1, presenilin 1; TBS, Tris-
buffered saline; TFR, transferrin receptor.
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Although most AD cases are sporadic without known genetic
mutations, Fe overloading appears to play an important role in
the cause and/or consequence of AD during the aging process.
Chelation therapy has been suggested as a valuable therapeutic
approach in neurological disorders (Bandyopadhyay et al., 2010).
Deferoxamine (DFO), a metal chelator commonly used
for the treatment of Fe overload, has been shown to have
neuroprotective effects in animal models of stroke (Hanson
et al., 2009), Parkinson’s disease (Haleagrahara et al., 2013),
age-induced loss of memory (de Lima et al., 2008). However,
adverse effects associated with systemic administration of DFO,
including systemic metal ion loss after long-term clinical
application and poor penetration through the blood-brain
barrier (BBB), have limited its use in this regard (Cuajungco
et al., 2000). Compared to the systemic delivery for a chronic
disease such as AD, nasal drug delivery system has a good
permeability and can be targeted to the central nervous
system (Yue et al., 2007), reducing systemic exposure with
possible side effects. We recently reported that intranasal
administered DFO can alter beta-amyloid (Aβ) precursor protein
(APP) processing, thereby decreasing β-Site APP cleaving
enzyme 1(BACE1) and presenilin-1 (PS1) protein expression
and resulting in the inhibition of Aβ deposition, neuritic
plaque formation, and memory deficit in APP/PS1 transgenic
mice (Guo et al., 2013a). Several molecular mechanisms
of action may take part in the beneficial neurotherapeutic
properties of DFO. One of the key mechanisms underlying
neuroprotection via Fe chelators is their antioxidant ability.
Chelators prevent Fe from redox cycling, thereby suppressing
hydroxyl radical formation via the Fenton reaction (Zecca
et al., 2004). Another important DFO-triggered neuroprotective
mechanism in AD may result from the stabilization and
transactivation of hypoxia-inducible factor-1alpha (HIF-1α)
pathway (Epstein et al., 2001; Jaakkola et al., 2001; Lando
et al., 2002), leading to transcriptional up-regulation of a
cassette of protective genes (Zaman et al., 1999; Siddiq et al.,
2005). However, whether the neuroprotective effect of intranasal
administered DFO on AD transgenic mouse brain is related
to the action of HIF-1α signaling pathway has not been fully
clarified.
HIF-1 was identified as a α/β heterodimer, that is involved in
hypoxic adaptation by transcriptionally inducing the expression
of HIF-1α target genes (Wang et al., 1995; Semenza, 1998).
Under hypoxia, HIF-1α is stable in the cytoplasm and can
dimerize with HIF-1β in the nucleus, and then mediate the
adaptation of cells to hypoxia by regulating the expression of
genes involved in erythropoiesis, angiogenesis, glucose transport,
and glycolysis, as well as genes relevant to Fe metabolism such
as transferrin and the transferrin receptor (TFR; Semenza, 1999;
Lee and Andersen, 2006; Tacchini et al., 2008). Interestingly,
oxygen and Fe are required for the inhibition of HIF-1α
activity (Ivan et al., 2001), thus Fe chelators can mimic
hypoxia and induce HIF-1α stabilization (Mecklenburgh et al.,
2002). Over the last decade, many studies have shown that
DFO, which also induces and stabilizes HIF-1 expression,
protects cultured cells from Aβ toxicity (Schubert and Chevion,
1995; Schubert et al., 2009) and inhibits AD progression
in patients (Crapper McLachlan et al., 1991). These studies
provided the clues to the possible involvement of HIF-1 in
neurodegenerative disorders, which is now becoming more
widely accepted.
However, despite the body of data suggesting that HIF-1
may be a good therapeutic target, more evidence is needed
to further clarify the involvement of the HIF-1 signaling
system in the neuroprotection contributed by Fe chelators in
neurodegeneration pathologies, especially in vivo. Thus, we
hypothesize that the neuroprotection exerted by DFO is in
part due to the elimination of the HIF-1α blockade. Here,
we examined the effectiveness of intranasal administration of
DFO for up-regulating HIF-1α levels and subsequently activating
proteins that are encoded fromHIF-1-adaptive genes in APP/PS1
mice and human neuroblastoma SH-SY5Y cells stably transfected
with human APP bearing the Swedish mutation (APPsw).
Additionally, we determined the possible signaling pathways
involved in this process.
Materials and Methods
Transgenic Mice and Treatments
The male APP/PS1 double transgenic mice used in this
study were originally obtained from Jackson Laboratory. All
experimental procedures were approved by the Laboratory
Animal Ethical Committee of Hebei United University.
Mice (aged 6 months) were randomly assigned to control
(n = 8) or DFO (n = 8) groups. DFO (Sigma D9533, 200 mg/kg
body weight, dissolved in saline) and vehicle were administered
intranasally once every other day for 3 months. For intranasal
administration, a 50-µl microsyringe was used to administer
four 6-µl nose drops (alternating nares with 2 min between
drops; 24 µl total; 5 mg DFO) to each mouse as described
in previous reports (Hanson et al., 2009). At the age of 9
months, the mice were decapitated. The brains were rapidly
removed and dissected into separate hemispheres on an ice-
cooled board. The hippocampus and cerebral cortex were
dissected from the left hemisphere and stored at −80◦C for
Western blot and reverse transcription (RT)-PCR analyses. The
right hemisphere was immersion fixed in 4% paraformaldehyde
in phosphate buffered saline at 4◦C overnight and routine
paraffin sections (5 µm) were prepared for morphological
analysis.
Fe Histochemistry with Perl’s Staining
Fe staining was performed on serial sections to analyze the
distribution of Fe in the brains of transgenic mice using 3, 3′-
diaminobenzidine-tetrahydrochloride (DAB)-enhanced staining
Perl’s staining. Briefly, sections (5 µm) were routinely dewaxed,
rehydrated, and treated in 0.1 M Tris-buffer saline (TBS,
pH 7.4) containing 3% hydrogen peroxide (H2O2) for 10
min to reduce endogenous peroxidase activity. The sections
were then immersed in Perl’s solution containing equal parts
of freshly made, aqueous potassium ferrocyanide (2%) and
hydrochloric acid (2%) for 30 min. After rinsing, the sections
were finally intensified with 0.025% DAB plus 0.0033% H2O2
in TBS for 10 min. The process was monitored under
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the microscope to avoid strong background staining, and
the duration of staining was the same for each animal.
After several washes with distilled water, the sections were
dehydrated, covered with neutral balsam and examined with
a light microscope equipped with a digital camera. All
slides were digitized using the optical fractionator technique.
The Fe-positive areas (number of pixels) from the brain
cortex and hippocampus were manually assessed using Adobe
Photoshop. The results were quantified with Image-Pro Plus 6.0
software.
Immunohistochemistry
Routine avidin-biotinylated complex (ABC) immuno-
histochemical staining was performed to analyze the distribution
of HIF-1α in the APP/PS1 transgenic mouse brain. Briefly,
paraffin sections were dewaxed, rehydrated and treated in
0.1 M TBS containing 3% hydrogen peroxide for 10 min to
reduce endogenous peroxidase activity. After washing with
TBS, sections were boiled in citric acid buffer for 3 min in
a microwave oven. The sections were then rinsed, treated
with 5% bovine serum albumin for 30 min, and subsequently
incubated overnight with rabbit anti- HIF-1α (1:200; Novus
NB100-479) at 4◦C. After rinsing, sections were incubated with
biotinylated goat anti-rabbit IgG (1:200) for 1 h, followed by
streptavidin peroxidase incubation for 1 h at room temperature.
After rinsing, the sections were stained with 0.025% DAB
for 3 min. The stained sections were dehydrated, cleared,
covered with neutral balsam, and examined under a light
microscope equipped with a digital camera. Control sections
were treated with identical solutions but without primary
antibody followed by all subsequent incubations as described
above.
Cell Culture, Drug Treatment
The APPsw cells were maintained in Dulbecco’s modified
Eagle’s medium and Ham’s F-12 nutrient mixture supplemented
with 10% heat-decomplemented fetal calf serum, 100 IU/mL
penicillin, 100 µg/mL streptomycin and 200 µg/mL G418 at
37◦C in humidified 5% CO2 air. Serum-free medium was added
for 2 h when cells reached nearly 70–80% confluence before
drug treatments. Cells were treated with FeSO4 (100 µM) or
SB203580 (10 µM, a P38 MAPK inhibitor) for 2 h and then
treated with DFO (100 µM). To ensure that the potential effects
of Fe and DFO on HIF-1α protein expression were not due to
treatment-induced cell death, the concentrations of Fe and DFO
selected were based on previously described studies (Guo et al.,
2013a). After 24 h, the cells were collected for Western blot
analysis.
Western Blotting
For Western blots, the APP/PS1 transgenic mouse brain
tissues and culture cells were homogenized in ice-cold lysis
buffer containing a mixture of protease inhibitors. After
homogenates were centrifuged at 12,000 rpm for 30 min
at 4◦C, supernatants were collected and the total protein
levels were measured using a UV 1700 PharmaSpec ultraviolet
spectrophotometer. Equal amounts proteins were resolved
in 10% sodium dodecyl sulfate polyacrylamide gels and
blotted on polyvinylidene fluoride membranes (Millipore,
CA, USA). After blocking in 5% non-fat milk for 1 h,
the membranes were incubated sequentially overnight at
4◦C with the following primary antibodies: rabbit anti-
APP695 (1:4000, Chemicon), rabbit anti- DIVALENT METAL
TRANSPORTER 1 (DMT1)-IRE (1:3000, Alpha diagnostic),
rabbit anti- DMT1-noIRE (1:3000, Alpha diagnostic), rabbit
anti- HIF-1α (1:1000, Novus), rabbit anti-p-JNK (1:1000, Cell
Signaling Tech), rabbit anti-JNK (1:1000, Cell Signaling Tech),
rabbit anti-p-ERK (1:1000, Cell Signaling Tech), rabbit anti-
ERK (1:1000, Cell Signaling Tech); rabbit anti-p-P38 (1:500,
Santa Cruz), rabbit anti-P38 (1:500, Santa Cruz); rabbit anti-
synaptophysin (SYP; 1:1000; Sigma-Aldrich); mouse anti-TFR
(1:1000, Invitrogen); mouse anti- brain-derived neurotrophic
factor (BDNF; 1:500, Chemicon), and mouse anti-GAPDH
(1:10000, Kang Chen, KC-5G5). After washing, the membranes
were incubated with horseradish peroxidase (HRP)-labeled
secondary antibodies (1:5000; Santa Cruz) for 1 h. Blots were
visualized using Super Signal West Pico Chemiluminescent
Substrate (Pierce Biotechnology, Rockford, IL, USA) and Chem
Doc XRS with Quantity One software (BioRad, USA). The band
intensities were quantified using Image-pro Plus 6.0 analysis
software.
RT-PCR
Total RNA was extracted from APP/PS1 transgenic mouse
brain tissue samples using Trizol (Invitrogen). After
quantification by UV-spectroscopy at 260 nm, total RNA
of each sample was first transcribed to cDNA using
EasyScriptTM Two-Step RT-PCR SuperMix (TransGen
Biotech, AE401). PCR amplification was performed with
reagents from TransGen Biotech. The cDNA solution was
amplified with sequences of the following primers: HIF-1α,
forward: TGGTATTATTCAGCACGAC, reverse: GAGACATT
GCCAGGTTTAT; glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), forward: ACGGATTTGGTCGTATTGGG, reverse:
CGCTCCTGGAAGATGGTGAT. The PCR conditions
were: HIF-1α, 30 cycles of 94◦C for 45 s, 50◦C for 45 s
and 72◦C for 45 s; GAPDH, 30 cycles of 95◦C for 45 s,
58◦C for 45 s, and 72◦C for 60 s. The PCR products
were normalized with reference to GAPDH mRNA. The
results were quantified with ChemDoc XRS Quantity One
software.
Immunohistochemistry and Confocal Laser
Scanning Microscopy
Cultured cells were seeded to sections. After treatment, cell
culture medium was carefully removed. After rinsing in PBS,
the cells were fixed in a freshly prepared solution of 4%
paraformaldehyde for 30 min. For immunofluorescent double
staining, sections or cell cultures were preincubated with normal
donkey serum (1:20; Jackson ImmunoResearch Laboratory)
for 30 min and then incubated overnight with either mouse
anti-Aβ (1:500; Sigma-Aldrich) and rabbit anti-SYP (1:200;
Sigma-Aldrich), or mouse anti-Aβ and rabbit anti-HIF-1α
(1:200). After three washing with PBS, the immunoreactivity
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was probed using Texas-Red or fluorescein isothiocyanate
(FITC) Green conjugated secondary antibodies (1:200; Jackson
ImmunoResearch Laboratory) for 2 h at room temperature.
After rinsing, the sections and cells were stained with DAPI
for 5 min. The images were observed by using a confocal laser
scanning microscope (SP2, Leica). No fluorescence is expected to
be detected when the primary antibody is omitted.
Statistical Analysis
All data are expressed as the mean ± standard error (S.E.).
Differences between means were evaluated with Student’s t-test,
and two-way ANOVA with Post hoc Fisher’s Protected Least
Significant Difference (PLSD) for cultured cells. All data were
analyzed using SPSS 13.0 software, and statistical significance was
assumed if p< 0.05.
Results
Intranasal DFO Treatment Modulated the
Distribution of Fe in the Brains of APP/PS1 Mice
We previously showed DFO did not attenuate the total content
of Fe in brains tissues of APP/PS1 mice when it was administred
(Guo et al., 2013a). In this study, brain sections from control
and APP/PS1 mice that were intranasally administered DFO
were subjected to Perl’s-DAB analysis as a relative measure of Fe
content within plaques and tissue. In general, Fe-positive plaques
were distributed throughout the cortex and hippocampus in all
examined animals (Figure 1), as previously described (Moreira
et al., 2010). Fe deposits were observed as brown granules.
In the cortex and hippocampus, many Fe-positive cells were
detected, most of which were neurons with cytoplasmic Fe
deposits, especially in the CA1 area of the hippocampus
(Figure 1A). Importantly, Fe ions were only detected in the
CA3 area of the hippocampus in untreated mice (Figure 1D),
while no significant changes were observed in the cortex and
the CA1 area of the hippocampus (Figures 1B,C). Thus, we
can infer that mediating the redistribution of Fe rather than
chelated Fe is probably responsible for inhibition of APP/Aβ
pathology in the brains of DFO-treated APP/PS1 transgenic
mice.
Intranasal DFO Treatment Reduced Synapse
Loss in APP/PS1 Mouse Brains
Previous studies have proposed that intranasal DFO
administration reduced the expression and phosphorylation
of APP protein by shifting the processing of APP to the non-
amyloidogenic pathway. This reduction was accompanied by
an attenuation of both the Aβ burden and tau phosphorylation,
and memory retention was significantly promoted in APP/PS1
mice (Guo et al., 2013a,b). In the present study, we then
assessed the effects of DFO on synapse lesion. As shown in
Figures 2A,B, Western blot analysis showed that DFO treatment
significantly increased the expression level of SYP compared
with control group. As further evidence of that, the positive area
of SYP staining was increased accompanied with a decreased
immunoreactive area of Aβ plaque in the brain of DFO-treated
APP/PS1 mice, compared with controls (Figure 2C). These
results suggest that intranasal DFO treatment reduce synapse
loss, and has a neuroprotective effect on the brain of APP/PS1
transgenic mice.
Effect of DFO on the Expression of HIF-1α and
Proteins that are Encoded from HIF-1-Adaptive
Genes in the Brains of APP/PS1 mice
The potential therapeutic effect of a Fe-chelating compound
may involve the activation of Fe-dependent prolyl hydroxylases,
which regulate HIF stability, leading to transcriptional up-
regulation of a cassette of target genes. In turn, the up-
regulation of these genes could contribute to neuroprotection
(Wang et al., 1995; Zaman et al., 1999). To investigate the
role of DFO in HIF-1α gene regulation, we first determined
the mRNA levels of HIF-1α in APP/PS1 mice brains by RT-
PCR analyses. As shown in Figure 3, the expression levels of
both HIF-1α protein (Figures 3A,B) and mRNA (Figures 3C,D)
were significantly increased after intranasal DFO treatment,
compared with the control mice (p < 0.01), indicating that
the drugs not only stabilized HIF-1α protein but influenced
its transcriptional regulation. Immunohistochemical staining
strengthened the biochemical results and further revealed that
intranasal DFO treatment caused not only accumulation but
also nuclear translocation of HIF-1α (Figure 3E). The HIF-1α
expressed in the control was almost exclusively distributed in the
cytoplasm of the neurons and rarely found in the nucleus. In
contrast, cells of the DFO-treated group in the cortex and dentate
gyrus of the hippocampus expressed high levels of HIF-1α in both
the cytoplasm and nucleus (Figure 3E).
Altogether, these results suggest that DFO has a positive effect
on HIF-1α gene and protein expression in the APP/PS1 mouse
brain.
To determine whether DFO-induced HIF-1α was
transcriptionally active, we further examined the effects of DFO
on the expression levels of selected downstream target proteins
of HIF-1α that might be involved in mediating Fe metabolism
and neuroprotection. Quantitative analyses of Western blots
revealed that treatment of APP/PS1 mice with DFO significantly
up-regulated the expression of BDNF, DMT1 + IRE, and TFR
proteins (p < 0.01; Figures 3F–H,J), whereas there were no
significant changes in the expression levels of DMT1-IRE
protein between the DFO-treated and control groups (p > 0.05;
Figures 3F,I). These results are consistent with previous reports
demonstrating that Fe deficiency results in HIF-1α stabilization
and the up-regulation of several HIF-dependent adaptive genes,
thereby coordinating the response to hypoxia conditions (Wang
et al., 1995; Soucek et al., 2003).
Effects of DFO on HIF-1α Regulatory Pathways
It has been reported that the mitogen-activated protein
kinase (MAPK) signaling pathway and phosphatidylinositol-
3-kinase (PI3K)/AKT signaling play important roles in
regulating HIF-1α expression (Blancher et al., 2001; Jiang
et al., 2001). Here, we investigated the activation of the three
MAPKs by Western blot analysis using phosphorylation-
specific MAPK antibodies in DFO-treated APP/PS1 mice
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FIGURE 1 | Fe accumulation in the cortex and hippocampus of APP/PS1
mice. (A) APP/PS1 transgenic mice were treated with control or DFO
(200 mg/kg) for 3 months before sacrifice. The right hemisphere of the brains
were quickly dissected, fixed in 4% paraformaldehyde in phosphate buffered
saline at 4◦C overnight, embedded in paraffin, cut into sections (5 µm) and
stained with modified Perl’s-DAB to reveal the distribution patterns of Fe ions in
the cortex and hippocampus. Fe deposits can be observed as brown granules.
In the cortex and hippocampus, there are many Fe-positive cells, most of which
are neurons with cytoplasmic Fe deposits, especially CA1 area of hippocampus.
Importantly, Fe ions were only detected in the CA3 area of the hippocampus
untreated mice. (B–D) Bar graphs illustrating the semi-quantitative Fe ions
densitometry measurements as percentages of the intact side. Scale
bar = 100 µm. These images are representative of 6 independent experiments,
all revealing similar results. **P < 0.01 vs. control group.
(Figure 4). Treatment with DFO induced a significant
decrease in phosphorylated ERK and JNK levels (p < 0.05,
Figure 4A; p < 0.01, Figure 4B). However, treatment with DFO
significantly increased the levels of p-P38 MAPK (p < 0.01,
Figure 4C) without affecting the total amounts of ERK, JNK,
and P38 MAPK proteins (Figure 4). These results suggest
that DFO-induced HIF-1α protein accumulation was, at
least in part, dependent on P38MAPK-mediated signaling
pathway.
DFO Inhibits Aβ Generation Involved in HIF-1α
Stabilization and the Expression of Proteins that
are Encoded Form HIF-1-Adaptive Genes in
APPsw Cells
To further investigate the mechanism underlying DFO-mediated
up-regulation of HIF-1α and the neuroprotective effect, we
examined the effects of DFO against ferrous Fe-induced toxicity
using Western blot analysis in vitro. To avoid the influence
of cell death in the following experiments, we have previously
explored the optimal concentrations of Fe andDFO, as following:
100 µM ferrous sulfate and/or 100 µM DFO (Guo et al.,
2013a). As shown in Figure 5, there were no significant
differences at the protein levels of HIF-1α, BDNF, DMT1 +
IRE, and TFR between the Fe group and the control cells.
However, in DFO-treated cells, chelation of Fe with 100 µM
DFO significantly increased the expression levels of HIF-1α,
BDNF, DMT1 + IRE, TFR proteins, respectively, compared
with the control cells (F = 7.014; F = 18.327; F = 15.216;
F = 8.835; p < 0.01; Figures 5E,F,H,I,K). Notably, HIF-1α
and DMT1 proteins in the Fe + DFO-treated cells were
significantly increased compared with their levels in control
cells (p < 0.01; Figures 5E,F,I). In addition, no differences
in the expression levels of DMT1-IRE were found between
the controls and any of the treatments (F = 1.965; p > 0.05;
Figures 5E,J).
Next, we also performed Western blot analysis to determine
the protein levels of APP695 in cells treated with DFO and/or
Fe. Immunoblotting revealed that, compared with controls,
treatment with Fe resulted in significantly increased levels
of APP695 protein (F = 11.590; p < 0.01, Figures 5E,G).
In contrast, the expression levels of APP695 in the DFO
group were significantly decreased compared with controls
(p < 0.01; Figures 5E,G). Moreover, these increases were
abolished when the cultures were treated with Fe followed by
DFO (F = 20.819; p < 0.01; Figures 5E,G). Double labeling
of Aβ (Figures 5A2–D2) and HIF-1α (Figures 5A1–D1)
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FIGURE 2 | Intranasal DFO treatment reduced synapse loss in APP/PS1
mouse brain. (A,B) Western blot analysis showed that DFO treatment
significantly increased the expression level of SYP compared with control group.
GAPDH was used as a loading control. (C) Immunofluorescence labeling and
confocal microscopy analysis showing the distribution and expression of SYP
(red) and Aβ (green) in brain sections of APP/PS1 mice. The positive area of
SYP staining was significantly increased following a decreased immunoreactive
area of Aβ plaque in the brain of DFO-treated APP/PS1 mice, compared with
controls. Scale bar = 100 µm. Data represent the mean ± S.E. of 6
independent experiments. **P < 0.01 vs. control group.
showed that treatment with Fe significantly increased the
Aβ immunofluorescence in APPsw cells compared with the
control (Figures 5A1,A2,B1,B2). DFO treatment decreased
the immunofluorescence intensity of Aβ but increased
HIF-1α immunoreactive intensity (Figures 5C1,C2) when
the cells were treated with Fe and DFO. Levels of HIF-1α
were detected in both the cytoplasm and the nucleus in
the DFO-treated cells. These results suggest that DFO
has an inhibitory effect on APP695 protein expression
and Aβ formation is involved in HIF-1α stabilization in
APPsw cells.
Collectively, these results further suggest that DFO
significantly induces HIF-1α accumulation, and promotes
nuclear translocation, and then suppresses the Aβ generation.
DFO up-Regulate HIF-1α Protein by the
Activation of P38 MAPK in APPsw Cells
To test the hypothesis that DFO may up-regulate the
HIF-1α signaling cascades by P38 MAPK activation in
APPsw cells, we further investigated the effect of DFO on
the activation of intracellular signaling proteins in APPsw
cells. As shown in Figure 6, strong phosphorylation of P38
MAPK was detected in the DFO-treated cells (F = 5.321;
p < 0.01; Figures 6A,B), whereas no significant changes
were observed in cells treated with Fe alone compared
with the control group. Interestingly, the total P38 MAPK
protein level, were not changed among the groups (p > 0.05;
Figures 6A,B).
Then, inhibition studies were carried out to investigate the
effect of signaling proteins in the DFO-mediated up-regulation
of HIF-1α. For this, APPsw cells were treated without or with
DFO in the absence or presence of SB203580. Immunoblotting
showed that DFO treatment at 24 h significantly increased the
phosphorylation of P38MAPK compared with the control group,
whereas the increase was significantly ameliorated by SB203580
(p< 0.01; Figures 6C,D). Profoundly, as shown in Figures 6C,E,
the DFO-mediated up-regulation of HIF-1α protein in APPsw
cells was greatly inhibited followed by the pretreatment with
SB203580.
Taken together, these data suggest that activities of P38
MAPK, specifically the phosphorylation of P38 MAPK,
contribute to the increased expression and activity of HIF-1α
protein in APPsw cells upon DFO treatment.
Discussion
DFO is a Fe chelator that has been shown to prevent AD
in a clinical trial and a range of disease models (Crapper
McLachlan et al., 1991; Savory et al., 1998; Morse et al., 2004;
Fine et al., 2012; Guo et al., 2013a,b). Our previous studies
have demonstrated that intranasal DFO treatment reverses
Fe-induced memory defects and inhibits amyloidogenic APP
processing and tau hyperphosphorylation in APP/PS1 mice
(Guo et al., 2013a,b). Despite these important advances,
the mechanisms of DFO-induced neuroprotection are not
completely understood. This present study was designed
to address the mechanism of intranasal DFO-induced
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FIGURE 3 | DFO regulates the expression of HIF-1α and
HIF-1-related protein in the brains of APP/PS1 mice.
(A) Western blots showing the expression levels of HIF-1α protein in
control and DFO-treated transgenic mice brains. (B) Immunoblot
showed that DFO treatment significantly increased HIF-1α protein
levels, compared with controls. (C) The expression levels of HIF-1α
mRNA were detected by RT-PCR in the brains of APP/PS1
transgenic mice treated with DFO. (D) RT-PCR analysis showed that
DFO treatment significantly increased the HIF-1α mRNA levels in the
transgenic mouse brain. GAPDH served as the internal control.
(E) Immunohistochemically stains showed the distribution of HIF-1α in
the cortical and hippocampus sections of APP/PS1 mouse brain
(Scale bar = 100 µm). (F) Western blots showing the expression
levels of brain-derived neurotrophic factor (BDNF), DMT1, and TFR
proteins in APP/PS1 transgenic mice brains 3 months after DFO
administration. GAPDH was used as a loading control. (G–J) DFO
treatment led to a marked increase in the BDNF, DMT1 + IRE, and
TFR protein levels in the brains of transgenic mice compared with the
control. There was no significant change in the expression levels of
DMT1-IRE protein between the groups, compared with the control.
Data represent the mean ± S.E. of 6 independent experiments.
**P < 0.01 vs. control group.
hypoxia signaling to further our understanding of the
therapeutic action of this agent in AD pathogenesis.
DFO treatment decreases the Aβ deposition and reduces
the synapse loss. More importantly, we extend previous
observations and demonstrate that DFO-induced HIF-1α
stabilization regulates Fe homeostasis and is a target for
neuroprotection. These neuroprotective mechanisms include
functional activation of HIF-1 signaling and regulation of
wide range of HIF-1-related adaptive proteins, such as
DMT1 + IRE, TFR and BDNF. Consequently, we have now
identified important roles of the P38 MAPKs in the intranasal
DFO-induced HIF-1α upregulation in APP/PS1 mice and
APPsw cells.
Fe chelators, which can possess Fe chelating ability for
removal of excess Fe in the brain, have the potential for
clinical use in neurological disorders, therefore, they have
been suggested as a potential noninvasive strategy for the
treatment of AD (Hanson et al., 2009; Fine et al., 2012; Guo
et al., 2013a). In this study, we found that Fe-containing cells
in the cortex and the CA1 area of hippocampus did not
significantly differ in amounts between the DFO-treated and
the control mice, whereas the levels of Fe in the Fe-positive
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FIGURE 4 | Expression levels of ERK, JNK, and P38 in the brains of
APP/PS1 mice 3 months after DFO treatment. (A) Western blots showing
the protein levels of ERK1/2 in the brains of transgenic mice. (A1,A2) There
were no significant differences in total ERK1/2 levels between the brains of
control and DFO-treated. However, the ratio of p-ERK1/2 to ERK1/2 was
significantly decreased after DFO treatment. (B) Immunoblot analyses showing
the expression levels of JNK1/2 in the brains of transgenic mice. (B1–B4) A
marked reduction in the ratio of p-JNK1/2 to JNK1/2 was detected in the brains
of DFO-treated mice, whereas there were no significant differences in total
JNK1/2 levels between the brains of control and DFO-treated mice. (C)
Western blots showing the protein levels of P38 in the brains of transgenic
mice. (C1,C2) There were no significant differences in total P38 levels between
the brains of control and DFO-treated mice. However, the ratio of p-P38 to P38
was markedly increased after DFO treatment. GAPDH was used as an internal
control. Data represent the mean ± S.E. of 6 independent experiments.
*p < 0.05, **p < 0.01 vs. control group.
cells in DFO-treated mice were significantly reduced in the
CA3 area of the hippocampus. Therefore, we presume that
the redistribution of Fe, rather than the removal of Fe from
the system, is most likely responsible for the neuroprotective
functions of DFO.
Recently, alternative mechanisms involving chelator exposure
were proposed for example, Fe chelator exposure can induce
the cellular stress response by activating adaptive signaling
proteins such as HIF-1α. This response triggers gene expression
shifts that increase the ability of the cell to tolerate elevated
levels of oxidative stress, and more importantly, cellular Fe
dyshomeostasis (Lee and Andersen, 2006). Indeed, previous in
vitro studies demonstrated that DFO treatment may cause a
decrease in mitochondrial reactive oxygen species (ROS) levels
in primary neurons, which then act as signaling molecules
for HIF-1 activation (Bianchi et al., 1999; Zaman et al.,
1999; Honda et al., 2005; Siddiq et al., 2005); the induction
of HIF-1α activation and gene signaling associated with Fe
homeostasis and metabolism (Lee et al., 1997; Rolfs et al.,
1997). The current study demonstrated that intranasal DFO
administration induced the mRNA expression of HIF-1α and
increased protein levels of HIF-1α in APP/PS1 mouse brains.
Subsequently, DFO significantly up-regulated the expression
levels of several adaptive HIF-1-related genes, such as BDNF
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FIGURE 5 | DFO inhibits Aβ generation involved in HIF-1α stabilization
and the expression of proteins that are encoded form HIF-1-adaptive
genes in APPsw cells. (A) Immunofluorescence labeling and confocal
microscopy analysis showing the distribution and expression of HIF-1α
(A1–D1) and Aβ (A2–D2) in APPsw cells. DFO treatment significantly
increased the HIF-1α immunofluorescence (D1) and reduced the Aβ
immunofluorescence (D2) in APPsw cells compared with the control
(A1,A2). (A3–D3) DAPI was used to detect the nucleus (blue). (A4–D4)
Merged images from the double channels indicated that DFO has an
inhibitory effect on Aβ formation is involved in HIF-1α stabilization in APPsw
cells. Fe treatment (100 µM) decreased the levels of HIF-1α (B1) and
increased the Aβ immunofluorescence (B2). The additional of DFO treatment
reversed the reduction of HIF-1α (C1) and the increase of Aβ (C2) in
cultures pretreated with 100 µM Fe. The images are a representative of
three independent experiments. Scale bar = 20 µm. (E) Western blot
analysis was performed to determine the expression levels of HIF-1α,
APP695, BDNF, DMT1, and TFR; GAPDH served as the internal control. (F)
There were no significant changes in HIF-1α levels in the Fe- or
Fe + DFO-treated groups compared with the controls. HIF-1α was markedly
increased after DFO treatment. In the Fe + DFO group, the level of HIF-1α
was significantly increased compared with that in the Fe treatment group.
(G) Fe treatment significantly increased the levels of APP695. In the Fe +
DFO group, the levels of APP695 were significantly decreased compared
with the Fe treatment group. DFO treatment significantly reduced the
expression level of APP695 compared with their levels in the controls.
(H–K) There were no significant changes in BDNF, DMT1 + IRE, and TFR
levels in the Fe-treated groups, whereas the level of DMT1 + IRE was
significantly increased in the Fe + DFO compared with the controls. The
level of BDNF, DMT1 + IRE, and TFR was significantly increased in the DFO
group, compared with the controls. No differences in the expression levels
of DMT1-IRE were found between the controls and any of the treatments.
Data represent the mean ± S.E. (n = 3). *p < 0.05, **p < 0.01 compared
with the control group; #p < 0.05, ##p < 0.01 compared with the Fe
treatment group (two-way ANOVA with Post hoc Fisher’s PLSD).
and the Fe homeostasis/metabolism protein DMT1 + IRE,
TFR, implying an additional neuroprotective mechanism of
DFO: induction of HIF-1α and regulation of Fe metabolism
in vivo (Semenza, 1998; Bergeron et al., 1999). These results
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FIGURE 6 | Roles of P38 mitogen-activated protein kinase
(MAPK) in the DFO-mediated up-regulate of HIF-1α protein in
APPsw cells. (A) APPsw were exposed to 100 µM Fe, 100 µM
DFO, or both combined for 24 h. Whole cell lysates were prepared
and subjected to analysis for P38 or GAPDH protein. (B) Western blot
analysis revealed that strong phosphorylation of P38 MAPK was
detected in the DFO-treated cells, whereas no significant changes
were observed in cells treated Fe alone compared with control. There
were not statistical changes in the levels of P38 MAPK among the
groups. The data represent the mean ± S.E. of three independent
experiments. *p < 0.05, **p < 0.01 compared with the control;
#p < 0.05,##p < 0.01 with respect to the Fe treatment group.
(C–E) APPsw cells were pretreated without or with SB203580 (10 µM)
for 2 h and then treated without or with DFO for additional 22 h in the
absence or presence of the inhibitor. Immunoblotting showed that DFO
treatment significantly increased the levels of p-P38 MAPK compared
with the control group, whereas the increase was significantly
ameliorated by SB203580. Furthermore, the DFO-mediated
up-regulation of HIF-1α protein was greatly inhibited by SB203580.
The data represent the mean ± S.E. (n = 3). **p < 0.01 compared
with the control; ##p < 0.01 compared to the values of DFO treatment
group (two-way ANOVA with Post hoc Fisher’s PLSD).
are further supported by the findings that increased levels of
HIF-1α were detected in both the cytosol and the nucleus
of cortical and hippocampal neurons in the DFO-treated
group. Additionally, studies with SH-SY5Y cells in vitro
demonstrated that epigallocatechin-3-gallate (EGCG) was to
confer neurorescue effects and significantly up-regulate the
expression of HIF-1 and its target gene TFR, the latter is
associated with Fe homeostasis (Reznichenko et al., 2006;
Weinreb et al., 2008). Interestingly, our study also demonstrated
that DFO elevates BDNF protein levels, which promotes
neuronal survival and differentiation (Thoenen, 1995, 2000;
Schinder and Poo, 2000). It also was reported that M30 increases
the expression levels of BDNF transcripts (Avramovich-Tirosh
et al., 2010), thereby inhibiting hypoxia-induced apoptosis
(Ruscher et al., 2002). To further corroborate the role of
HIF-1α in the pathogenesis of AD, we embarked in a series
of in vitro experiments. In accordance, our in vitro findings
demonstrated that DFO up-regulated expression of HIF-1α
and several HIF-1α target proteins in APPsw cells, which was
accompanied by a reduction in APP695 protein expression
and Aβ generation. This can be viewed that the regulation
of HIF-1α expression and its related targets may constitute
an additional pathway underlying the neuroprotective effect
of DFO.
Notably, the modulation of the HIF pathway appears to be
complex. Some proteins have been shown to stimulate HIF-1α
transactivation or synthesis by activation of the MAPK or the
PI3K signaling pathways (Zelzer et al., 1998; Li et al., 2004;
Lonati et al., 2014). To elucidate the molecular mechanism
for the DFO induced HIF-1α stabilization and activation, we
evaluated the total and activated forms of ERK1/2, JNK1/2, and
P38 because they have been also implicated in involving APP
processing with increased Aβ deposition (Atkins et al., 1998;
Savage et al., 2002; Kim et al., 2006; Cho et al., 2007; Lee et al.,
2009). Here, we showed that the phosphorylation of ERK1/2
and JNK was attenuated in the DFO-treated group in vivo. Our
data are in agreement with a very recent study describing that
green tea catechin, an iron chelator, may decrease in behavioral
impairment, Aβ-42 production, and activation of ERK and
JNK MAPK in NSE/hAPP-C105 transgenic mice (Lim et al.,
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2013). Interestingly, we observed that under our experimental
conditions, DFO enhanced P38 MAPK phosphorylation in
cultured APPsw cells and brains of treated APP/PS1 mice. It has
been reported that different MAPKs are activated by different
stimuli and target different downstream molecules; therefore,
they each perform different functions (Schaeffer and Weber,
1999; Roux and Blenis, 2004). Therefore, these alterations in
the expression of MAPK family members induced by DFO
treatment provide vital information about the mechanism of
DFO action during AD treatment. Further, we observed in
vitro that inhibitors of P38 block HIF-1α upregulation by DFO
treatment. These results, and the demonstration of P38 MAPK
elevation in both human APPsw cells and AD mouse brains,
suggest that P38 MAPK is a central mediator of hypoxia-induced
neuroprotection in AD. The notion that DFO might regulate
HIF-1α via phosphorylation of MAPK/P38 signaling pathway
will be addressed in greater depth in future studies.
Taken together, the present results suggest that the
neuroprotective effects of DFO may be correlated, at least
in part, with the ability of this Fe chelator to activate the
transcriptional activator HIF-1α and up-regulate HIF-1α-
mediated protective genes, especially these targets involving in
Fe metabolism. Our data further indicate that HIF-1 may prevent
AD occurrence, postpone AD progression, and ameliorate AD
symptoms by regulating the expression of its target genes.
Thus, Fe chelators, and specifically intranasal administration
of DFO, might be beneficial for their potent efficacy in the
prevention and treatment of neurodegenerative diseases such as
AD.
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